" class="no-js "lang="en-US"> Asklepios BioPharmaceutical (AskBio) - Medtech Alert
Tuesday, March 21, 2023
Asklepios BioPharmaceutical (AskBio) | Pharmtech Focus

Asklepios BioPharmaceutical (AskBio)

About Asklepios BioPharmaceutical (AskBio)

Asklepios BioPharmaceutical (AskBio)

A gene therapy company changing lives with every genetic advancement

At Asklepios BioPharmaceutical (AskBio), we are making history with every clinical advancement and aspire to turn hope into cures by unraveling new possibilities for genetic medicine. We became a wholly owned, independently operated subsidiary of Bayer AG in late 2020 as a cornerstone of its newly formed Cell & Gene Therapy Platform.

AskBio is headquartered in Research Triangle Park, North Carolina, a thriving biotechnology hub with nearly 600 life science companies, and has additional research and development facilities in Edinburgh, Scotland, and Paris, France, and gene therapy manufacturing in San Sebastian, Spain.

Started in 2001, we are on a never-ending quest to advance genetic technology and life-saving gene therapy. We are singularly focused on a goal to erase genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.

Almost 40 years ago, AskBio’s scientific co-founder, Jude Samulski, PhD, was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. His groundbreaking research propelled the most exciting field in medical research today. His work inspires our world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.

Related Story

BrainVectis, a Subsidiary of AskBio, Receives Clearance to Conduct Phase I/II Clinical Trial in France for Its Novel Gene Therapy for Early-stage Huntington’s Disease

August 24 2022

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, has […]

AskBio Announces IND for LION-101 Cleared to Proceed by U.S. FDA

May 26 2021

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that […]